Effect of chronic treatment with milnacipran on sleep architecture in rats compared with paroxetine and imipramine
Effect of chronic treatment with milnacipran on sleep architecture in rats compared with paroxetine and imipramine
复制标题
DOI：
10.1016/s0091-3057(02)00812-2
复制
发表时间：
2002-10-01
影响因子：
3.6
通讯作者：
Luppi, PH
中科院分区：
文献类型：
--
作者：
Gervasoni, D;Panconi, E;Luppi, PH
在人类和其他物种中的许多研究表明，长期使用抗抑郁药，如三环类或选择性5-羟色胺再摄取抑制剂（SSRIs），会导致快速眼动（REM）睡眠减少或抑制。研究了一种新的选择性5-羟色胺和去甲肾上腺素再摄取抑制（NRI）抗抑郁药米那普仑对REM睡眠的影响，并与SSRI、帕罗西汀和三环类药物丙咪嗪进行了比较。每天两次注射载体或米那普仑的大鼠在24小时内显示出与对照大鼠相似的REM睡眠量、REM睡眠发作的次数和持续时间。相比之下，用丙咪嗪或帕罗西汀急性治疗的大鼠显示出REM睡眠总量的统计学显著减少。快速眼动睡眠发作的次数减少，而持续时间增加。更详细的分析进一步表明，在上午9点注射米那普仑后的前4小时，而不是在下午7点注射米那普仑后的前6小时，帕罗西汀后的前6小时，以及丙咪嗪后的整个明-暗期间，REM睡眠的数量减少。对于所有药物，24小时内的慢波睡眠和清醒的数量与对照条件没有显着差异，停药后一天内没有发生REM睡眠反弹。功率谱分析显示，在清醒、慢波睡眠或REM睡眠期间，控制条件和不同治疗之间的不同脑电图（EEG）波（δ、θ、γ）没有全局变化。总之，我们的结果表明，SNRI，米那普仑，在治疗剂量，诱导只有轻微的干扰REM睡眠相比，SSRI和三环类抗抑郁药使用。对米那普仑对REM睡眠作用差异的可能机制进行了讨论。(C)2002年爱思唯尔科技有限公司All rights reserved.
A number of studies in humans and various other species have shown that chronic treatment with antidepressants, such as tricyclics or selective serotonin reuptake inhibitors (SSRIs), induces a decrease or suppression of rapid eye movement (REM) sleep. The effect of a new selective serotonin and noradrenaline reuptake inhibiting ( NRI) antidepressant, milnacipran, on REM sleep has been investigated and compared with that of the SSRI, paroxetine, and the tricyclic, imipramine. Rats injected with vehicle or milnacipran twice a day showed, over 24 h, a similar amount of REM sleep, number and duration of REM sleep episodes to control rats. In contrast, rats treated acutely with imipramine or paroxetine showed a statistically significant decrease in the total quantity of REM sleep. The number of REM sleep episodes was decreased while their duration was increased. A more detailed analysis showed further that the quantity of REM sleep was decreased for the first 4 h following the 9 a.m. injection but not the 7 p.m. injection for milnacipran, during the first 6 h for paroxetine and for the entire light-dark period for imipramine. For all drugs, the quantities of slow-wave sleep and waking over 24 h were not significantly different from control conditions and no rebound of REM sleep occurred during the day following withdrawal. Power spectrum analysis revealed no global changes in the different electroencephalogram (EEG) waves (delta, theta, gamma) between the control condition and the different treatments during waking, slow-wave sleep or REM sleep. Taken together our results indicate that the SNRI, milnacipran, at therapeutic doses, induces only minor disturbances of REM sleep compared with a SSRI and tricyclic antidepressant used. Possible mechanisms responsible for the difference of action on REM sleep of milnacipran are discussed. (C) 2002 Elsevier Science Inc. All rights reserved.